S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
3 Free Stock Picks per Day (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
3 Free Stock Picks per Day (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:MGTA

Magenta Therapeutics (MGTA) Stock Forecast, Price & News

$0.64
+0.01 (+1.59%)
(As of 05/26/2023 03:59 PM ET)
Compare
Today's Range
$0.62
$0.65
50-Day Range
$0.62
$0.81
52-Week Range
$0.32
$2.24
Volume
126,400 shs
Average Volume
1.25 million shs
Market Capitalization
$38.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Magenta Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
212.5% Upside
$2.00 Price Target
Short Interest
Healthy
0.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
1.44mentions of Magenta Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.82) to $0.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Medical Sector

91st out of 1,010 stocks

Pharmaceutical Preparations Industry

33rd out of 494 stocks


MGTA stock logo

About Magenta Therapeutics (NASDAQ:MGTA) Stock

Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA.

Receive MGTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGTA Stock News Headlines

WARNING TO ALL U.S. INVESTORS
May 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Magenta Therapeutics (MGTA) Receives a Hold from H.C. Wainwright
MGTA Magenta Therapeutics, Inc.
See More Headlines
Receive MGTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGTA Company Calendar

Last Earnings
11/04/2021
Today
5/29/2023
Next Earnings (Estimated)
5/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGTA
Fax
N/A
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+212.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-76,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.75 per share

Miscellaneous

Free Float
53,638,000
Market Cap
$38.82 million
Optionable
Not Optionable
Beta
2.09

Key Executives

  • Stephen Frank Mahoney
    President, Chief Financial & Operating Officer
  • Lisa M. Olson
    Chief Scientific Officer & Head-Research
  • Cindy Driscoll
    Senior Vice President-Finance
  • Catherine Monaghan
    Head-Clinical Development Operations
  • Thomas W. Beetham
    Secretary & Chief Legal Officer













MGTA Stock - Frequently Asked Questions

Should I buy or sell Magenta Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MGTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MGTA, but not buy additional shares or sell existing shares.
View MGTA analyst ratings
or view top-rated stocks.

What is Magenta Therapeutics' stock price forecast for 2023?

5 Wall Street research analysts have issued 1-year price targets for Magenta Therapeutics' stock. Their MGTA share price forecasts range from $1.00 to $3.00. On average, they anticipate the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 212.5% from the stock's current price.
View analysts price targets for MGTA
or view top-rated stocks among Wall Street analysts.

How have MGTA shares performed in 2023?

Magenta Therapeutics' stock was trading at $0.3950 at the beginning of 2023. Since then, MGTA stock has increased by 62.0% and is now trading at $0.64.
View the best growth stocks for 2023 here
.

Are investors shorting Magenta Therapeutics?

Magenta Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 408,800 shares, a decline of 56.0% from the April 30th total of 930,000 shares. Based on an average daily volume of 514,400 shares, the short-interest ratio is currently 0.8 days. Approximately 0.9% of the shares of the stock are sold short.
View Magenta Therapeutics' Short Interest
.

When is Magenta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 29th 2023.
View our MGTA earnings forecast
.

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics, Inc. (NASDAQ:MGTA) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03.

What ETF holds Magenta Therapeutics' stock ?

Harbor Disruptive Innovation ETF holds 40,742 shares of MGTA stock, representing 0.10% of its portfolio.

What is Jason Gardner's approval rating as Magenta Therapeutics' CEO?

3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP).

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Who are Magenta Therapeutics' major shareholders?

Magenta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (6.25%), TCW Group Inc. (1.24%), Acadian Asset Management LLC (1.01%), Renaissance Technologies LLC (0.65%), RBF Capital LLC (0.41%) and Susquehanna International Group LLP (0.30%). Insiders that own company stock include Bruce Booth, Kristen Stants and Rock Ventures Iv LP Third.
View institutional ownership trends
.

How do I buy shares of Magenta Therapeutics?

Shares of MGTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $0.64.

How much money does Magenta Therapeutics make?

Magenta Therapeutics (NASDAQ:MGTA) has a market capitalization of $38.82 million. The company earns $-76,460,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.magentatx.com. The company can be reached via phone at (857) 201-2700 or via email at investor@magentatx.com.

This page (NASDAQ:MGTA) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -